Back to Search
Start Over
The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
- Source :
- Kidney international, Vol. 99, p. 34-47 (2021), Kidney International, 99(1), 34-47. ELSEVIER SCIENCE INC, Kidney international, Vol. 99, no.1, p. 34-47 (2021)
- Publication Year :
- 2020
- Publisher :
- Elsevier, 2020.
-
Abstract
- Chronic kidney disease (CKD) causes substantial global morbidity and increases cardiovascular and all-cause mortality. Unlike other chronic diseases with established strategies for screening, there has been no consensus on whether health systems and governments should prioritize early identification and intervention for CKD. Guidelines on evaluating and managing early CKD are available but have not been universally adopted in the absence of incentives or quality measures for prioritizing CKD care. The burden of CKD falls disproportionately upon persons with lower socioeconomic status, who have a higher prevalence of CKD, limited access to treatment, and poorer outcomes. Therefore, identifying and treating CKD at the earliest stages is an equity imperative. In 2019, Kidney Disease: Improving Global Outcomes (KDIGO) held a controversies conference entitled "Early Identification and Intervention in CKD." Participants identified strategies for screening, risk stratification, and treatment for early CKD and the key health system and economic factors for implementing these processes. A consensus emerged that CKD screening coupled with risk stratification and treatment should be implemented immediately for high-risk persons and that this should ideally occur in primary or community care settings with tailoring to the local context.
- Subjects :
- 0301 basic medicine
Cost effectiveness
030232 urology & nephrology
Psychological intervention
detection
risk stratification
Kidney
urologic and male genital diseases
law.invention
COST-EFFECTIVENESS
0302 clinical medicine
Randomized controlled trial
Risk Factors
law
glomerular filtration rate
CLINICAL-PRACTICE GUIDELINE
CYSTATIN C
creatinine
female genital diseases and pregnancy complications
Nephrology
medicine.symptom
alburninuria
health systems
medicine.medical_specialty
Context (language use)
Risk Assessment
CARDIOVASCULAR OUTCOMES
03 medical and health sciences
Intervention (counseling)
medicine
CKD
MANAGEMENT
Humans
Albuminuria
Renal Insufficiency, Chronic
Intensive care medicine
Socioeconomic status
cost-effectiveness
cystatin
interventions
PRIMARY-CARE IDENTIFICATION
business.industry
screening
risk models
medicine.disease
INTENSIVE GLUCOSE CONTROL
RANDOMIZED-TRIAL
kidney failure
030104 developmental biology
proteinuria
business
INDIVIDUAL PARTICIPANT DATA
chronic kidney disease
Kidney disease
Subjects
Details
- Language :
- English
- ISSN :
- 00852538
- Database :
- OpenAIRE
- Journal :
- Kidney international, Vol. 99, p. 34-47 (2021), Kidney International, 99(1), 34-47. ELSEVIER SCIENCE INC, Kidney international, Vol. 99, no.1, p. 34-47 (2021)
- Accession number :
- edsair.doi.dedup.....2de5fe9137310aa28e49c898892bba1b